{"entity":{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","aka":[],"tldr":"A phase 2 trial of Abexinostat in diffuse large b-cell lymphoma, run by Xynomic Pharmaceuticals, Inc., now recruiting.","summary":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT03936153 by Xynomic Pharmaceuticals, Inc., with 170 participants planned, started 2020-01-20 and due to reach its primary completion in 2026-07-31. Interventions recorded: abexinostat. Conditions listed: Diffuse Large B-cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03936153","url":"https://clinicaltrials.gov/study/NCT03936153"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["abexinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03936153","phase":"2","setting":"An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Xynomic Pharmaceuticals, Inc.","enrolled":170,"outcomes":[]},"route":"/trials/nct03936153/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/"}]}}